172 completed, 52 recruiting, 36 unknown, 30 active not recruiting. 143 Phase 2, 119 Phase 3, 67 Phase 1, 19 Not applicable, 16 Phase 4.
Follow this drug Literature Review of Daunorubicin trials Research Report on Daunorubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia Daunorubicin, Cytarabine, Liposome Mitoxantrone - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 320 | 2026-09-30 | 2026-08-26 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-10-20 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations VEN combined with azacitidine, Cytarabine plus Daunorubicin - Acute Myeloid Leukemia, NPM1 Mutation | Phase 2 | Not yet recruiting | Shen yang | 148 | 2026-07-01 | 2026-06-24 |
| A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients Revumenib, Cytrabine, Daunorubicin - Pediatric Acute Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-05-21 | 2026-09-23 | |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 300 | 2026-04-30 | 2026-03-25 |
| A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia BL-M11D1, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 216 | 2026-04-02 | 2026-09-10 |
| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) Bleximenib, Cytarabine, Daunorubicin or Idarubicin - Acute Myeloid Leukemia | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 875 | 2026-03-01 | 2026-10-08 |
| Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 102 | 2025-12-12 | 2026-10-20 |
| Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy daunorubicin, cytarabine liposomes, Azacitidine, Venetoclax - Leukemia, Myeloid, Acute | Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-10 | 2025-06-03 | |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML Ziftomenib, Placebo, Venetoclax - Acute Myeloid Leukemia (AML) | Phase 3 | Recruiting | Kura Oncology, Inc. | 1300 | 2025-09-26 | 2026-10-13 |
| Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients Daunorubicin/Idarubicin, Cytarabine, Azacitidine - AML, Adult | Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 240 | 2025-08-31 | 2026-03-02 |
| The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). - AML (Acute Myelogenous Leukemia), Down Syndrome (DS) | Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 100 | 2025-07-24 | 2025-11-20 |
| Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) Bortezomib, CPX-351 - Acute Myeloid Leukemia, TP53 | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 32 | 2025-07-07 | 2026-07-22 |
| Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML Venetoclax, Azacitidine (AZA), Daunorubicin - Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 50 | 2025-06-20 | 2026-10-13 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-21 |
Showing 20 of 334. Sign in to see all of them.
Leukemia, Myeloid, Acute (159) · Leukemia (96) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (86) · Leukemia, Monocytic, Acute (31) · Leukemia, Myelomonocytic, Acute (31) · Leukemia, Erythroblastic, Acute (27) · Congenital Abnormalities (25) · Leukemia, Megakaryoblastic, Acute (25) · Burkitt Lymphoma (20) · Myelodysplastic Syndromes (19) · Lymphoma (17) · Leukemia, Biphenotypic, Acute (15) · Anemia, Refractory, with Excess of Blasts (11) · Myeloproliferative Disorders (10) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (9)
National Cancer Institute (NCI) (43) · Children's Oncology Group (32) · Institute of Hematology & Blood Diseases Hospital, China (18) · St. Jude Children's Research Hospital (15) · PETHEMA Foundation (8) · SWOG Cancer Research Network (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Gruppo Italiano Malattie EMatologiche dell'Adulto (6) · Memorial Sloan Kettering Cancer Center (6) · Eastern Cooperative Oncology Group (5) · M.D. Anderson Cancer Center (5) · Novartis Pharmaceuticals (5) · University of Ulm (5) · Alliance for Clinical Trials in Oncology (4) · Goethe University (4)
United States (187) · Canada (58) · Australia (46) · Germany (46) · China (38) · France (32) · Italy (27) · Puerto Rico (26) · Switzerland (26) · Spain (22) · United Kingdom (22) · Austria (19) · Belgium (17) · Czechia (17) · Netherlands (16)
Alan K. Burnett, MD, FRCP (3) · Dieter Hoelzer, MD, PhD (3) · Dieter Hoelzer, MD,PhD (3) · Guido Marcucci (3) · Hui Wei, MD (3) · Richard Stone, MD (3) · Thomas R. Chauncey, MD, PhD (3) · Xiaofan Zhu, MD (3) · Alan S. Gamis, MD, MPH (2) · Allen Yeoh, MBBS (2)
PMID 36184192, PMID 31171508, PMID 31375516, PMID 37267439, PMID 36815378, PMID 38295280, PMID 39121442, PMID 41671463, PMID 42085603, PMID 23007406, PMID 24383844, PMID 24970932, PMID 25527568, PMID 33242441, PMID 34048072, PMID 38446568, PMID 16105981, PMID 16421426, PMID 19144982, PMID 19433688, PMID 19546402, PMID 20154213, PMID 21719599, PMID 22442346, PMID 22493293, PMID 22627678, PMID 22649106, PMID 22965967, PMID 23233662, PMID 24344215, PMID 24816240, PMID 26888258, PMID 26913693, PMID 27561722, PMID 28751559, PMID 29148893, PMID 29720733, PMID 29926156, PMID 30138085, PMID 30337300, PMID 30523055, PMID 31188727, PMID 31601692, PMID 31612640, PMID 32552472, PMID 32589970, PMID 33152759, PMID 33496745, PMID 34162404, PMID 34596937
U10CA180886 (16), U10CA098543 (14), U10CA031946 (12), U10CA032102 (7), U10CA180821 (7), U10CA180888 (5), 2014 (4), 2017 (4), U10CA021115 (4), 2018 (3), 2023 (3), P30CA006973 (3), P30CA012197 (3), U10CA180820 (3), UM1CA186712 (3)